![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 48, 49624-49632, November 26, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





¶

¶||
From the
Departments of
Radiation Oncology and Molecular Radiation Sciences,
Oncology, and ¶Urology, The Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231
DNA damage that is not repaired with high fidelity can lead to chromosomal aberrations or mitotic cell death. To date, it is unclear what factors control the ultimate fate of a cell receiving low levels of DNA damage (i.e. survival at the risk of increased mutation or cell death). We investigated whether DNA damage could be introduced into human cells at a level and frequency that could evade detection by cellular sensors of DNA damage. To achieve this, we exposed cells to equivalent doses of ionizing radiation delivered at either a high dose rate (HDR) or a continuous low dose rate (LDR). We observed reduced activation of the DNA damage sensor ataxia-telangiectasia mutated (ATM) and its downstream target histone H2A variant (H2AX) following LDR compared with HDR exposures in both cancerous and normal human cells. This lack of DNA damage signaling was associated with increased amounts of cell killing following LDR exposures. Increased killing by LDR radiation has been previously termed the "inverse dose rate effect," an effect for which no clear molecular processes have been described. These LDR effects could be abrogated by the preactivation of ATM or simulated in HDR-treated cells by inhibiting ATM function. These data are the first to demonstrate that DNA damage introduced at a reduced rate does not activate the DNA damage sensor ATM and that failure to activate ATM-associated repair pathways contributes to the increased lethality of continuous LDR radiation exposures. This inactivation may reflect one strategy by which cells avoid accumulating mutations as a result of error-prone DNA repair and may have a broad range of implications for carcinogenesis and, potentially, the clinical treatment of solid tumors.
Received for publication, August 20, 2004
* This work was supported by an NCI program project grant and an NCI Specialized Programs of Research Excellence grant from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|| To whom correspondence should be addressed: Dept. of Radiation Oncology and Molecular Radiation Sciences, Cancer Research Bldg., Rm. 144, 1650 Orleans St., Baltimore, MD 21231. Tel.: 410-614-3979; Fax: 410-502-7234; E-mail: deweete{at}jhmi.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. Sgouros, S. J. Knox, M. C. Joiner, W. F. Morgan, and A. I. Kassis MIRD Continuing Education: Bystander and Low Dose-Rate Effects: Are These Relevant to Radionuclide Therapy? J. Nucl. Med., October 1, 2007; 48(10): 1683 - 1691. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sokolov, I. G. Panyutin, and R. Neumann Genome-wide gene expression changes in normal human fibroblasts in response to low-LET gamma-radiation and high-LET-like 125IUdR exposures Radiat Prot Dosimetry, December 1, 2006; 122(1-4): 195 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Vilenchik and A. G. Knudson Radiation dose-rate effects, endogenous DNA damage, and signaling resonance PNAS, November 21, 2006; 103(47): 17874 - 17879. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |